08:50
Chair’s opening remarks
09:00
Biprocessing-Fill&finish for bioprocessing and hazards associated: Derisking approach
Mostafa Nakach, Head of Pharma Eng, Sanofi Aventis France Sa
09:30
Dr Simon Hartas, Director, Product Development UK/US, AstraZeneca
Keynote panel discussion: Utilising formulation and delivery strategies to differentiate and gain commercial success
Dr Simon Hartas, Director, Product Development UK/US, AstraZeneca
10:15
Embracing QbD to aid pharmaceutical development
10:45
Speed Networking followed by morning refreshments
The Speed Networking session is a great way for you to meet your fellow conference attendees in a fast and dun session. Bring lots of business cards, as you have only have time to meet, greet and exchange cards with your table of peers before rotating onto the next table. Get to know some friendly faces, and continue those conversations later on in the conference at lunch, breaks or the evening's party.
11:45
• Drug Delivery best practice
• Formulation strategies to satisfy unmet patient needs
• Regulatory challenges in formulation development
• Strategies to improve bioavailability
• Understanding how novel delivery methods are evaluated for market access
13:45
Approaches to phase 1 development
Mike Frodsham, Pharmaceutical Development Manager, Quay Pharma
14:15
Designing the right preformulation strategy: The building blocks of formulation
14:45
Lab Automation and stability prediction of bioproducts
15:15
Emerging trends in drug formulation and delivery
15:45
Afternoon refreshments
16:15
Drug Formulation: Influence in Efficacy and Safety
- How does formulation affect drug delivery?
- How does formulation effect drug efficacy and safety?
- Examples of dermal-formulation efficacy and safety
Jorge Ignacio González Borroto, Pharmacovigilance Department, Ferrer Internacional Sa
16:45
Adare pharmaceuticals transforms medicines, creating new possibilities for improved patient health. For decades, Adare has successfully overcome complex formulation challenges in specialized and diverse therapeutic categories, such as cardiovascular, pain management, and virology, delivering medicines that benefit patients. Using proprietary technologies- including taste masking and ODTS, customising drug release, and bioavaliability enhancement. The company has demonstrated the unique ability to transform drug formulations and create novel Rx and OTC products. Additionally, Adare has extensive expertise in adding value IP to new and existing products. With global R&D and manufacturing facilities, Adare has the capacity to bring complex products from development to commercialisation.
Adare Pharmaceuticals-A Patient-Centric Approach to Drug Formulation
Adare pharmaceuticals transforms medicines, creating new possibilities for improved patient health. For decades, Adare has successfully overcome complex formulation challenges in specialized and diverse therapeutic categories, such as cardiovascular, pain management, and virology, delivering medicines that benefit patients. Using proprietary technologies- including taste masking and ODTS, customising drug release, and bioavaliability enhancement. The company has demonstrated the unique ability to transform drug formulations and create novel Rx and OTC products. Additionally, Adare has extensive expertise in adding value IP to new and existing products. With global R&D and manufacturing facilities, Adare has the capacity to bring complex products from development to commercialisation.
17:15
Dissolution rate limiting AUC: simple methodology for measuring dissolution rate of the entire dose in biorelevant media
17:45
Aggregation and particle characterization
18:15
Chair's Closing remarks
last published: 16/Nov/15 16:55 GMT
